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ABSTRACT
Endometriosis is a major cause of chronic pelvic pain and
infertility. Activation of STAT3 appears central to the inflam-
matory phenotype of eutopic endometrium in women with
endometriosis. However, the molecular mechanism by which
this occurs remains unknown. Our objective is to determine how
STAT3 activity is regulated in endometriosis. Protein inhibitor of
activated STAT3 (PIAS3) is a negative regulator of STAT3
activity. We examined the levels of PIAS3 in endometrium from
women with and without endometriosis using Western blot
analysis and immunohistochemistry. Levels of PIAS3 are
significantly lower, in contrast with phosphorylation of STAT3,
in women with endometriosis compared to women without
endometriosis. Furthermore, induction of endometriosis in the
baboon showed a significant reduction of PIAS3 expression
during the progression of the disease. Interferon-c (INFc)
reduces PIAS3 protein levels and increases phospho-STAT3
levels through CXCL10 in endometrial cells, Ishikawa, and 12Z
cells. These results suggest that attenuation of PIAS3 causes
aberrant activation of STAT3 in endometriosis, leading to
inflammatory changes that may impair fertility or cause pain.
cytokine, endometriosis, endometrium, PIAS3, STAT3
INTRODUCTION
Endometriosis, defined as the presence of endometrial cells
outside of the uterine cavity, is a major cause of infertility and
pelvic pain. It affects .5% of reproductive age women [1].
Endometriosis results in significant health care costs, upwards
of $22 billion per year in the United States [2]. Endometriosis
likely contributes significantly to other common disorders,
including irritable bowel syndrome, interstitial cystitis, and
chronic fatigue syndrome [1, 3]. Endometriosis is strongly
associated with infertility, but only 50% of women with
endometriosis are infertile [4, 5]. Such heterogeneity among
women with endometriosis makes it difficult to assign a true
cause-and-effect relationship between endometriosis and infer-
tility. The distribution of ectopic endometriosis tissue is most
often within the pelvic peritoneum but can include the ovary,
pelvic viscera, rectovaginal septum, pleura, abdominal wall,
and, rarely, the brain [6, 7]. Pelvic endometriosis lesions are
thought to derive predominantly from retrograde menstruation,
which occurs in nearly all women [8, 9]. Endometriosis is
treated by surgical removal of lesions and/or hormonal
suppression focused on reducing estrogen, such as progestins,
androgens, gonadotropin-releasing hormone (GnRH) agonists,
and aromatase inhibitors. However, both approaches are
associated with various side effects and a high incidence of
relapse [1, 10]. Therefore, identification of mechanisms
involved in the pathogenesis of endometriosis and strategic
therapies for treatment are critical.
Endometriosis is an estrogen-dependent inflammatory
condition, and inflammatory components play key roles in
the pathogenesis of endometriosis [1]. A variety of cytokines,
including leukemia inhibitory factor, interleukin-6 (IL-6), IL-
11, and epidermal growth factor, can activate the signal
transducer and activator of transcription (STAT) family of
transcription factors, specifically STAT3 [8–11]. STAT3 is
localized in the cytoplasm until activated by phosphorylation.
On activation, STAT3 are phosphorylated by Janus kinase
(JAK) and then form homo- or heterodimers that translocate to
the cell nucleus, where they act as transcription activators [12].
STAT3 has an important role as signal transducer and regulator
of gene expression critical to normal cellular processes,
including cell development, differentiation, proliferation,
survival, angiogenesis and immune function [13]. However,
excessive activation of STAT3 leads to a number of tumor-
promoting processes, including maintenance of the stem cell,
block differentiation, promotion of growth and angiogenesis,
and regulation of the immune response and tumor microenvi-
ronment [14–16]. STAT3 has been used as a cancer therapeutic
target because it plays a pivotal role in oncogenic functions and
immunosuppression [17]. Additionally, levels of phosphoryla-
tion of STAT3 are significantly higher in eutopic endometrium
from women with endometriosis compared to women without
endometriosis, and aberrant activation of STAT3 signaling
plays an important role in pathogenesis of endometriosis [18,
19]. However, STAT3 signaling has not been studied enough
as a therapeutic target for endometriosis.
In normal cells, STAT activation is rapid and transient
because it is negatively regulated by regulator proteins, such as
SOCS and protein inhibitor of activated STAT3 (PIAS3) [20,
21]. PIAS3 is identified as a primary inhibitor of STAT3.
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PIAS3 binds to the STAT3 DNA binding domain and
inhibits the STAT3 transcriptional activity by physical
prevention [21, 22]. PIAS3 is also found to be a regulator
protein of other key transcription factors, including microph-
thalmia-associated transcription factor, nuclear factor kappa-
light-chain-enhancer of activated B cells, and SMADs [23–25].
Most of the proteins that are known to be modulated by PIAS3
play an essential role in the immune system. However, the
function of PIAS3 has not been studied in the endometrium and
endometriosis.
In this study, we examined the levels of STAT3 regulators
in endometrium from women with and without endometriosis.
The levels of PIAS3 were significantly lower in endometrium
from women with endometriosis compared to the control. We
showed that interferon-c (INFc) suppressed the expression of
PIAS3 and phosphorylated the STAT3 through CXCL10 in
endometrial cells, Ishikawa, and 12Z cells. Therefore, our
results suggest that attenuation of PIAS3 causes aberrant
activation of STAT3 in the pathogenesis of endometriosis.
MATERIALS AND METHODS
Human Subjects
The human endometrial samples used to examine PIAS3 expression
patterns were obtained from Michigan State University’s Center for Women’s
Health Research Female Reproductive Tract Biorepository, the University of
North Carolina, and the Greenville Hospital System in accordance with the
guidelines set by the Institutional Review Boards of Michigan State University
(Grand Rapids, MI), the University of North Carolina (Chapel Hill, NC), and
the Greenville Health System (Greenville, SC), respectively. Written informed
consent was obtained from all participants. For experiments examining PIAS3
expression patterns in the eutopic endometrium of women with and without
endometriosis at secretory stage, control samples were compared to
endometriotic samples obtained. The human endometrial samples were used
for Western blot (10 samples per group) and immunohistochemistry analysis
(16 samples per group).
Animals and Tissue Collection
The endometriosis baboon animal model is reviewed and approved by the
Institutional Animal Care and Use Committees of both the University of Illinois
at Chicago and Michigan State University. Endometriosis is induced by
intraperitoneal inoculation of menstrual endometrium on two consecutive
menstrual cycles and harvested using laparotomy via endometriectomy from
five female baboons as previously described [26]. Laparotomies were
performed at 3, 6, and 9 mo postinoculation to harvest the eutopic endometrial
tissues. Eutopic endometrial tissues were used for immunohistochemistry
analysis.
Western Blot Analysis
Western blot analyses were performed as described previously [27].
Proteins were extracted using lysis buffer (150 mM NaCl, 0.125% Nonidet P-
40 [vol/vol]), 10 mM Tris-HCl (pH 7.4), 2.5 mM EDTA, a protease inhibitor
cocktail (Roche, Indianapolis, IN) and a phosphatase inhibitor cocktail (Sigma
Aldrich, St. Louis, MO). Equal amounts of total protein (20 lg) were resolved
via SDS-polyacrylamide gel electrophoresis and transferred onto polyvinyli-
dene difluoride membrane (Millipore Corp., Bedford, MA). Membrane was
blocked with 0.5% Casein for 2 h at room temperature followed by overnight
incubation with 1:1000 diluted anti-PIAS3 (ab22856; Abcam, Cambridge,
MA), anti-SOCS1 (ab3691; Abcam), anti-SOCS2 (48-584; Prosci Inc., Poway,
CA), anti-SOCS3 (ab16030; Abcam), anti-SOCS4 (ab118530; Abcam), anti-
SOCS5 (ab97283; Abcam), anti-SOCS6 (ab13950; Abcam), anti-pSTAT3
(9131; Cell Signaling, Danvers, MA), anti-STAT3 (4904; Cell Signaling), or
anti-HIF1A (61275; Active Motif, Carlsbad, CA) antibodies. Immunoreactivity
was visualized by incubation with a horseradish peroxidase-linked secondary
antibody and developed by ECL reagents (GE Healthcare Biosciences,
Piscataway, NJ). To control for loading, the membrane was stripped, probed
with anti-Actin (sc1616; Santa Cruz Biotechnology, Santa Cruz, CA), and
developed. The band intensity was determined by relative densitometry using
ImageJ (National Institutes of Health) and normalized against the bands
obtained for Actin.
Immunohistochemistry
Immunohistochemistry analysis was performed as previously described
[27]. The paraffin-embedded uterine tissues were cut into 6-lm sections,
mounted on silane-coated slides, deparaffinized, and rehydrated in a graded
alcohol series. Sections were blocked with 10% normal goat serum in PBS (pH
7.5) and then incubated with anti-PIAS3 (ab22856; Abcam; dilutions: 1:1000),
anti-pSTAT3 (9131; Cell Signaling; dilutions: 1:100), or anti-STAT3 (4904;
Cell Signaling; dilutions: 1:1000) antibodies in PBS supplemented with 10%
normal goat serum overnight at 48C. The next day, sections were incubated
with secondary antibody conjugated to horseradish peroxidase (Vector
Laboratories, Burlingame, CA) for 1 h at room temperature. Immunoreactivity
was detected using diaminobenzidine (DAB; Vector Laboratories) and then
counterstained with hematoxylin and coverslipped with permount. Immuno-
staining was analyzed using microscopy software from NIS Elements, Inc.
(Nikon, Melville, NY).
Statistical Analysis
Statistical analyses were performed using the Student t-test for data with
two groups. For data containing more than two groups, we performed an
analysis of variance test and analyzed by Tukey or Bonferroni test for pairwise
t-test. All data are presented as means 6 SEM; P , 0.05 was considered
statistically significant. All statistical analyses were performed using the Instat
package from GraphPad (San Diego, CA).
RESULTS
Levels of PIAS3 in Eutopic Endometrial Tissue from Women
with Endometriosis
Phosphorylation of STAT3 appeared central to the inflam-
matory phenotype of eutopic endometrium in women with
endometriosis [18, 19]. To determine how the regulation of
phosphorylation of STAT3 in endometriosis contributes to
infertility, we examined the levels of STAT3 regulators,
including six suppressors of cytokine signaling (SOCS) and
protein inhibitor of activated STAT3 (PIAS3), phospho-
STAT3, and hypoxia inducible factor 1 a (HIF1A), a STAT3
target protein, in endometrium from women with and without
endometriosis at secretory stage. As it is known [28], the levels
of phospho-STAT3 (pSTAT3) and HIF1A proteins were
increased in endometrium from women with endometriosis
compared to controls. The levels of SOCS1-3 protein were not
different between the endometrium with endometriosis, and
those without endometriosis but SOCS4 levels were lower in
endometriosis (Supplemental Fig. S1; Supplemental Data are
available online at www.biolreprod.org). Interestingly, the
levels of PIAS3 protein were significantly decreased in
endometrium from women with endometriosis compared to
controls. In contrast, the levels of pSTAT3 were increased in
the endometrium of endometriosis patients compared to
controls (Supplemental Fig. S1 and Fig. 1).
To examine the cell-specific expression of PIAS3, pSTAT3,
and STAT3, we next performed immunohistochemical analysis
of PIAS3, pSTAT3, and STAT3 in endometrium from women
with and without endometriosis at the secretory stage using
serial section. PIAS3 proteins were strongly detected in
epithelial cells but weakly observed in stromal cells of
endometrium without endometriosis (Fig. 2A). Levels of
PIAS3 were significantly lower in the epithelial and stromal
compartments in endometrium from women with endometri-
osis compared to women without endometriosis. In contrast,
phosphorylation levels of STAT3 were higher in the endome-
trium from endometriosis patients compared to controls. Total
levels of STAT3 protein were not different between them (Fig.
2). The IgG antibody was intended for use as a negative control
with PIAS3, pSTAT3, and STAT3 proteins in the endometrium
(Supplemental Fig. S2). These results suggest that attenuation
YOO ET AL.
2 Article 11
of PIAS3 may play an important role in the pathogenesis of
endometriosis through STAT3 signaling.
PIAS3 Expression During Progression of Endometriosis in
the Baboon Model
Animal models are useful for studying the temporal
sequence of events involved in disease establishment and
progression. The baboon model has previously been developed
to study the pathophysiology of endometriosis [29–31]. To
determine if aberrant expression of PIAS3 was also evident in
the baboon model, we examined PIAS3 expression in the
eutopic endometrium of baboons at the secretory phase
following experimental induction of endometriosis by immu-
nohistochemical analysis. PIAS3 were strongly detected in the
endometrium of preinoculation (control) baboons. However,
levels of PIAS3 were significantly decreased at 6 and 9 mo
postinoculation during endometriosis progression. In contrast,
levels of pSTAT3 were strongly detected in the baboon
endometrium following induction of the disease, but total
levels of STAT3 protein were unchanged (Fig. 3). The IgG
antibody was intended for use as a negative control with
PIAS3, pSTAT3, and STAT3 proteins in the baboon
endometrium (Supplemental Fig. S3). These results suggest
that PIAS3 is related to the pathogenesis of endometriosis.
Suppressed Expression of PIAS3 mRNA in Endometrial
Cells Treated with Interferon-c (INFc) Through CXCL10
A number of inflammatory factors showed increases after
hormone withdrawal [32]. The interferon-gamma (IFN-c)-
induced protein (CXCL10) was increased in human endome-
trial stromal cells after progesterone withdrawal [32]. CXCL10
is secreted by several cell types, such as monocytes, endothelial
FIG. 1. Levels of PIAS3 in endometrium from women with and without endometriosis. A) Representative result of PIAS3, pSTAT3, and STAT3 by Western
blot analysis in endometrium from women with and without endometriosis. B) Quantification of PIAS3 protein levels by Western blot data in
endometrium from women with and without endometriosis obtained by densitometric analysis. The results represent the mean 6 SEM. ***P , 0.001.
FIG. 2. Comparison of PIAS3 expression in the endometrium between women with and without diagnosed endometriosis. A) Representative
photomicrograph of immunohistochemical staining of PIAS3 (a and b), pSTAT3 (c and d), and STAT3 (e and f) in the endometrium from women without (a,
c, and e) or with endometriosis (b, d, and f). Bars ¼ 25 lm. B) The immunohistochemical H-score of PIAS3 expression in the endometrium between
women with and without diagnosed endometriosis. The results represent the mean 6 SEM. ***P , 0.001.
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cells, and fibroblasts, in response to IFN-c [33]. To determine
if CXCL10 induces PIAS3 expression, we treated Ishikawa,
human endometrial adenocarcinoma cells with CXCL10 and
subsequently used quantitative PCR and Western blot analysis
to examine the expression levels of PIAS3. Levels of PIAS3
mRNA expression were decreased by more than eightfold in
Ishikawa cells treated with CXCL10 within 1 hour (Fig. 4A).
Additionally, levels of PIAS3 protein were reduced in Ishikawa
cells treated with CXCL10 after 2 h (Fig. 4B). These results
suggest that CXCL10 is a negative regulator of PIAS3
expression in endometrial epithelial cells.
Next, we treated Ishikawa and 12Z, endometriotic epithelial
cell line cells with IFN-c for 24 h and measured PIAS3,
pSTAT3, and total STAT3 protein levels by Western blot
analysis. The expression of PIAS3 was reduced by IFN-c in a
dose-dependent manner in Ishikawa cells as well as 12Z cells.
In contrast, phosphorylation of STAT3 protein was increased
by IFN-c in a dose-dependent manner in these cells (Fig. 5).
This result demonstrates that IFN-c appears to be a negative
regulator of PIAS-3 via CXCL10 in endometrial epithelial
cells.
DISCUSSION
Endometriosis is an estrogen-dependent chronic inflamma-
tory disease affecting fertility. Inflammation can lead to an
anatomic disorder and plays an important role in the
pathogenesis of endometriosis [1]. According to previous
studies, STAT3 is significantly implicated in inflammatory
responses. STAT3 can be activated by a variety of cytokines,
including leukemia inhibitory factor, IL-6, IL-11, and epider-
mal growth factor [8, 9]. STAT3 is a key signal transducer and
regulator of gene expression critical to normal cellular
processes, including cell development, differentiation, prolif-
eration, survival, angiogenesis, and immune function [13].
However, the function of STAT3 has not been studied enough
in the development of endometriosis. Previously, we found that
phosphorylated STAT3 is higher in endometrium of women
with endometriosis compared to subjects without endometri-
osis. Additionally, phosphorylation of STAT3 can be remark-
ably increased by IL-6, and HIF1A, one of the STAT3 target
genes, is elevated and significantly correlated with STAT3
phosphorylation in endometrium of women with endometriosis
compared to those without endometriosis [18]. Progesterone
resistance is a well-established phenomenon seen in endome-
triosis and the eutopic endometrium [34]. Progesterone favors
the stimulation of STAT5 [35], which is an inhibitor of STAT3
[36]. We recently published a review of the central role of
STAT3 signaling on the alterations in endometrial receptivity
[37]. This study showing that STAT3 signaling is dysregulated
by reduced PIAS3 may provide further insight into the
FIG. 3. PIAS3 expression in endometrium in baboon endometriosis model. A) Representative photomicrograph of immunohistochemical staining of
PIAS3 (a–d), pSTAT3 (e–h), and STAT3 (i–l) in endometriosis baboon models induced by intraperitoneal inoculation of menstrual endometrium during
progression of endometriosis in preinoculation (a, e, and i) at 3 (b, f, and j), 6 (c, g, and k), and 9 (d, h, and l) mo. Bars ¼ 25 lm. B) The
immunohistochemical H-score of PIAS3 in the endometriosis baboon model induced by intraperitoneal inoculation of menstrual endometrium during
progression of endometriosis in preinoculation at 3, 6, and 9 mo. The results represent the mean 6 SEM. **P , 0.01 and ***P , 0.001.
FIG. 4. Effect of PIAS3 expression by treatment with CXCL10. RT-PCR (A)
and Western blot (B) analysis for PIAS3 after treatment with CXCL10 over
time in Ishikawa cells.
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development and progression of endometriosis but also provide
information related to treatment options for women with
infertility.
First, we examined levels of inhibitors of activated STAT3,
such as SOCS and protein inhibitor of activated STAT3
(PIAS3), to determine how the regulation of the phosphory-
lation of STAT3 functions in endometriosis. PIAS3 protein
levels were lower in endometrium from women with
endometriosis compared to those without endometriosis. In
normal conditions, activation of STAT is rapid and transient
because it is regulated negatively by proteins such as SOCS
and PIAS3 [20, 21]. We found that SOCS levels were not
different between women with and without endometriosis,
except in SOCS4. SOCS proteins inhibits STAT3 signaling by
inhibiting the kinase activity of Janus kinase through direct
binding [20, 38, 39]. However, PIAS3 can inhibit activity by
interacting with the STAT dimer and blocking transcription
[21, 22]. These results demonstrate that PIAS3 may be an
important inhibitor of STAT3 signaling in the development and
progression of endometriosis independent of SOCS protein
changes.
We observed the novel finding that the expression level of
PIAS3 was significantly reduced in the endometrium of women
with endometriosis compared to women without endometriosis.
We also confirmed that PIAS3 expression levels were
significantly decreased in baboon endometriosis animal models
during endometriosis progression. The ontogeny of inflamma-
tion in the endometrium is demonstrated in the baboon model.
As we recently showed, it is difficult to remove the
inflammation by surgery alone [40], suggesting that this is a
systemic disease of inflammation that, once established, is
perpetuated by recurrent menses or continued presence of
implants. It apparently takes time after inoculation for the
inflammation in the pelvis to be recognized by the immune
system and then begin to be reflected in the endometrium. This
model suggests it takes many months before the changes are
showing up in the endometrium, of which 40% are immune
cells. There are no immediate differences in the preinoculation
and 3-mo images. The decrease is associated with the onset of
progesterone resistance [26, 41–44]. At 3 mo, the endometrium
is primarily estrogenic, and progesterone-regulated genes are
not affected, so it would be expected to look like the controls.
Additionally, PIAS3 proteins were strongly detected in the
nucleus of human and baboon endometrial epithelial cells.
However, the expression of PIAS3 was weakly detected in
some stromal cells. Taken together, we suggest that PIAS3 may
have an important role in the pathogenesis of endometriosis.
CXCL10 has been found to inhibit growth, angiogenesis,
and metastasis in experimental tumors [45–47]. CXCL10 was
reported to be elevated after progesterone withdrawal,
associated with menstrual-related inflammation [32]. Several
studies suggest that the down-regulated CXCL10 correlated
with poor patient prognosis in human cancer and the
suppression of CXCL10 expression result in drastic tumor
growth and metastasis that accelerate tumor advancement [48,
49]. Additionally, levels of CXCL10 in serum and peritoneal
fluid of women with advanced endometriosis are significantly
lower compared to women without endometriosis [50].
Therefore, more research is needed about the role of CXCL10
in endometriosis. PIAS3 expression levels were rapidly
decreased in Ishikawa cells treated with CXCL10. Further-
more, PIAS3 protein levels were reduced in Ishikawa cells and
12Z treated with dose-dependent IFN-c upstream of CXCL10.
However, we do not have direct evidence about the IFN-c
suppressed expression of PIAS3 by CXCL10 in this study.
Therefore, there is a need to investigate in order to explain a
molecular mechanism of IFN-c-CXCL10 signaling to regulate
PIAS3 expression. Other related factors that interfere with
PIAS3 cannot be ruled out. Nitric oxide (NO) has been shown
to destabilize PIAS3 in other cell types [51]. NO synthase has
been shown to be elevated in women with infertility and
endometriosis [52], which may be induced by STAT3
activation via IL-6-mediated mechanisms [53].
PIAS3 may be a targetable molecule for the treatment of
inflammatory conditions, such as endometriosis. In published
studies, curcumin suppresses activation of STAT3 in ovarian
and endometrial cells through up-regulation of PIAS3 [54].
Overall, these findings show for the first time that PIAS3 is
reduced in women with endometriosis. IFN-c reduces PIAS3
and increases activity of STAT3, perhaps through CXCL10.
The activation of STAT3 associated with inflammation appears
to be due, in part, to aberrant regulatory pathways involving
overexpression of stromal CXCL10. Activation of STAT3 and
downstream events affecting endometrial receptivity appear to
be a central feature of endometriosis. STAT3 and PIAS-3
represent new therapeutic targets for the treatment of
endometriosis.
FIG. 5. Levels of PIAS3 protein by IFN-c in a dose-dependent manner in Ishikawa and 12Z cells. Western blot analysis of PIAS3, pSTAT3, and STAT3 in
Ishikawa (A) and 12Z (B) cells treated with IFN-c in a dose-dependent manner for 24 h. Actin was used as loading control.
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